tbuckley/cabot-search huggingface dataset:
P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability
Authors: A F Kessler, C Schaeffer, M Burek, U Ruschig, R Ernestus, M Löhr, C Förster, C Hagemann
Journal: Neuro-Oncology (2018)

Brain tumors, especially glioblastoma multiforme (GBM), the most aggressive primary brain tumor in adults, are difficult to treat, because cerebral microvessels strictly regulate the transfer of substances between blood and brain tissue. Thereby they prevent clinical application of several promising drugs. This limitation in drug transport is due to the blood-brain barrier (BBB), mainly formed by intercellular tight junctions (TJ) between brain capillary endothelial cells. Recently, Tumor Treating Fields (TTFields), alternating electric fields with low intensity and intermediate frequency, have been introduced as a new adjuvant treatment modality for GBM. Here, the effect of TTFields on BBB permeability is investigated. Immortalized murine brain capillary endothelial cells (cerebEND) were grown on coverslips and transwell inserts. Cells were treated with TTFields at a frequency of 100–300 kHz for up to 72 h. Cell morphology was analyzed by immunofluorescence staining of the TJ proteins Claudin 5 and ZO-1. BBB integrity was determined by transendothelial resistance (TEER) and BBB permeability by flow cytometry analysis with fluoresceine isothiocyanate (FITC). TTFields application disturbs the BBB by delocalization of tight junction proteins from the cell boundaries to the cytoplasm with most dramatic effects at 100 kHz. The effects appear after 24 h and are most severe after 72 h TTFields treatment. The BBB integrity was significantly reduced by 65% and the BBB permeability for 4 kDa large molecules was significantly increased upon TTFields application. The cell morphology started to recover 48 h and was completed 96 h after end of TTFields treatment pointing to a reversibility of the TTFields-effect on the BBB. TTFields at a frequency of 100 kHz may potentially permeabilize the BBB. Thereby, TTFields could be utilized to deliver drugs usually unable to cross the BBB to the central nervous system. The presented in vitro data will be verified in an in vivo setting and hopefully may lead to a phase I clinical trial and clinical application in the future.
Modification of PLGA Scaffold by MSC‐Derived Extracellular Matrix Combats Macrophage Inflammation to Initiate Bone Regeneration via TGF‐ <i>β</i> ‐Induced Protein
Authors: Moyuan Deng, Jiulin Tan, Chengshen Hu, Tianyong Hou, Wei Peng, Juan Liu, Bo Yu, Qijie Dai, Jiangling Zhou, Yusheng Yang, Rui Dong, Changshun Ruan, Shiwu Dong, Jianzhong Xu
Journal: Advanced Healthcare Materials (2021)

Adv. Healthcare Mater. 2020, 9, 2000353 DOI: 10.1002/adhm.202000353 Since the publication of this paper, the authors have noted that an error in Figure 5C, in which representative crystal violet staining image for M2 macrophages of the PLGA group was incorrect. The corrected figure is shown below. This change made do not affect the conclusion drawn in this study. The authors apologize for any inconvenience caused to the readers by this change.
The computer-stored medical record
Authors: Clement J. McDonald, William M. Tierney
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Two diametrically opposite approaches are being marketed to solve hospitals' information-processing problems.<sup>1,2</sup>The first follows a centralized model where all processing software is purchased from a single vendor. The other follows a distributed model and interconnects the independent systems, eg, laboratory, pharmacy, and order entry systems, systems that might already exist in a hospital. We argued that the fastest way for most hospitals to create an automated hospital record system is to draw on the data that already exist, including those stored in independent laboratory and pharmacy systems when they are present. However, we were describing current opportunities, not arguing for a future reality. Whether the centralized or distributed model will be predominant in the future is not a question to argue in a learned journal; it is a question the marketplace will decide. We accept that Drs Korpman and Lincoln's persuasive arguments for a centralized,
BASIC SCIENCES
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 20934: Chronic Polarization of Inflammatory Monocytes by Super-Low Grade Endotoxin Aggravates the Pathogenesis of Atherosclerosis
Authors: Shuo Geng, Ruoxi Yuan, Liwu Li
Journal: Circulation (2017)

The subclinical levels of Gram negative bacterial endotoxin, LPS, circulating in the blood are prevalent in the individuals with adverse health conditions or lifestyles. LPS is a potent agent in the dynamic programming of monocytes, and altered innate immune homeostasis mediated by non-resolving inflammatory monocytes has long been suspected in the pathogenesis of atherosclerosis. However, the mechanisms responsible for the sustainment of inflammatory monocytes during atherosclerosis are poorly understood. We hypothesized that the selective modulation of molecular switches in monocytes by super-low dose LPS may facilitate the establishment of non-resolving inflammation during atherosclerosis. We challenged high-fat-diet (HFD) fed ApoE deficient mice with chronic LPS administration, and observed that LPS effectively induced expansion of Ly6C high pro-inflammatory monocytes with elevated levels of CCR5, MCP-1, and reduced SR-B1. Compare to PBS administration, chronic injection of super-low dose LPS significantly elevated the lipid deposition within the atherosclerotic plaques in HFD fed ApoE deficient mice, while induced remarkable reduction in collagen content of the plaques. To test whether the LPS reprogrammed monocytes, instead of systemic effects of LPS, may contribute the exacerbation of atherosclerosis, we performed adoptive transfer experiment. Bone-marrow monocytes harvested from ApoE deficient mice were primed in vitro with super-low dose LPS for 5 days, and then intravenously injected into HFD fed ApoE once weekly for 1 month. We observed significant increases of the plaque sizes as well as lipid deposition in atherosclerotic lesions, indicating that programmed monocytes directly aggravated atherosclerosis progression. At the molecular level, we observed that monocytes programmed by super-low dose LPS maintained higher levels of transcription factor IRF5 and reduced levels of a critical inflammatory repressor, Blimp-1. Intriguingly, the inflammatory monocyte priming by super-low dose LPS was dependent upon TRAM/TRIF but not MyD88. In conclusion, our data suggest super-low grade LPS may program sustained low-grade inflammatory monocytes that are conducive for the chronic pathogenesis of atherosclerosis.
<i>Etudes sur la raqe el la methode Pasteur, par le Dr. Lutaud, Rédacleur ren chef du Journal de Médecine de Paris. 2d édition. Précédée d'une lettre de M. le Professeur Peter et contenant les statistiques complétes depuis l'inauguration de la méthode jusqu'en 18th.</i>Paris, Journal de Médecine de Paris. l2mo; pp. x, 440. (Studies on rabies amud Pasteur's method, by Dr. Lumtaud, editor in chief of the Journal de Medecine de Paris. 2d. edition. Preceded by a letter of Professor Peter, and …
Journal: American Journal of Psychiatry (1891)
A new strategy for the surgical treatment of aortic coarctation associated with ventricular septal defect in infants using an absorbable pulmonary artery band
Authors: D. Bonnet, D. Tamisier, J. Patkai, D. Sidi, P. Acar, J. Kachaner, P.R. Vouhe
Journal: Journal of the American College of Cardiology (1998)
Metabolism and Toxicity of trans,trans-Muconaldehyde, an Open-Ring Microsomal Metabolite of Benzene
Authors: Gisela Witz, Louise Latriano, Bernard D. Goldstein
Journal: Environmental Health Perspectives (1989)

We have previously hypothesized that ring-opened metabolites may play an important role in benzene tox- icity.In this paper we review recent work related to this hypothesis.trans,trans-Muconaldehyde (TTM), a six-carbon diene dialdehyde, was shown by our laboratory to be a microsomal metabolite of benzene.This compound is a ring-opened metabolite of benzene that is hematotoxic in mice.The toxicity of TTM may stem in part from its ability to act as a direct-acting alkylating agent involving interaction with cellular sulfhydryls and/or amino groups.On the other hand, metabolism to the diacid trans,trans-muconic acid (MA), a known urinary metabolite of benzene, may represent detoxification since this results in toss of electrophilicity of the compound.Preliminary results indicate that TTM can be metabolized to MA in vitro and in vivo.The interaction of TTM in vitro with macrophages and neutrophils, key cells in the bone marrow, results in cell membrane changes, including loss of activity in the plasma membrane-bound NADPH-dependent oxidase and decreases in membrane lipid fluidity.Deoxyguanosine also was found to react with TTM, forming several different products.These findings may be due to TTM acting directly as an alkylating agent.
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results.
Authors: W. Janni, T. Sarosiek, C. A. Papadimitriou, J. V. Álvarez Gallego, M. Caruso, W. Wiest, M. L. Lim, H. Andersson, A. Das-Gupta
Journal: Journal of Clinical Oncology (2011)

e11097^ Background: Lapatinib (L), a dual kinase inhibitor of EGFR and ErbB2, is approved for the treatment of ErbB2+ MBC in combination with capecitabine (C) following progression after trastuzumab, anthracylines, and taxanes. Vinorelbine (V) is an important chemotherapy option in MBC, and multiple Phase II trials have been conducted in combination with trastuzumab. Methods: This randomized, open-label, multicentre, Phase II study (LAP112620, VITAL) is evaluating the efficacy and safety of L with either V or C in women with ErbB2+ MBC. 105 patients with disease progression who have received ≤1 chemotherapy regimen in the metastatic setting are randomized 2:1 to either L 1250 mg orally once daily (QD) continuously plus V 20mg/m2 intravenously on days 1 and 8, every third week, or L 1250 mg orally QD continuously plus C 2000 mg/m2/day orally in 2 doses 12 hours apart on days 1-14 every third week. The primary endpoint is progression-free survival. As initial dose-selection was based on 2 ongoing Phase I trials, an interim safety cohort (n=30) is employed with prospectively determined stopping rules for the L+V arm based on clinically-acceptable limits for febrile neutropenia (5%) and Grade (G) 4 neutropenia (20%). Utilizing 95% confidence intervals (CI), these limits may be exceeded with 4 events in 20 patients (20%) for febrile neutropenia and 9 events in 20 (45%) patients for G4 neutropenia. Results: The safety cohort (n=20 LV arm + 10 LC arm) completed a minimum of 3 cycles. Median daily exposure to L was 1250mg vs 1212mg in the LV and LC arm, respectively. 33% and 66% of patients received first-line vs second-line therapy, respectively, for MBC. Most common Grade 3-5 toxicities (>10%) for LV vs LC arms were G3 neutropenia (10% vs 0%), G4 neutropenia (10% vs 0%), G3 diarrhea (10% vs 20%), G3 leukopenia (10% vs 0%). In the LV arm, febrile neutropenia and G4 neutropenia were noted in 1 (5%) and 2 (10%) patients, respectively. The lower bounds of the 95% CI did not exceed the clinically acceptable thresholds. Conclusions: The pre-planned interim safety analysis supports the current dose selection of L 1250mg + V 20mg/m2. Recruitment into this trial continues.
Rape
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physician leadership in preventing AIDS
Authors: C. E. Koop
Journal: JAMA (1987)

This week's<i>JAMA</i>includes "Prevention and Control of Acquired Immunodeficiency Syndrome [AIDS]: An Interim Report,"<sup>1</sup>a report from the American Medical Association's (AMA) Board of Trustees. This report is part of the continuing joint efforts of the AMA, the Public Health Service, other health professional organizations, and the community at large to prevent and contain the spread of human immunodeficiency virus (HIV). The AMA is to be commended for its foresight and progressive approach. Acquired immunodeficiency syndrome is not like any disease or syndrome we have faced before. By its nature, AIDS raises unnecessary fear and unwarranted complacency at the same time. Its complexity causes misunderstandings. However, in the area of prevention, the prevention message of the Surgeon General's report on AIDS<sup>2</sup>is as valid now as when it was issued almost a year ago. The report of the AMA Board of Trustees reinforces and expands on these
Therapeutics
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Section 57.—Infantile Cortical Hyperostosis (Caffey's Disease)
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
Authors: James W Denham, David Joseph, David S Lamb, Nigel A Spry, Gillian Duchesne, John Matthews, Chris Atkinson, Keen-Hun Tai, David Christie, Lizbeth Kenny, Sandra Turner, Nirdosh Kumar Gogna, Terry Diamond, Brett Delahunt, Chris Oldmeadow, John Attia, Allison Steigler
Journal: The Lancet Oncology (2018)
High-dose methaqualone inhibits platelet aggregation
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interplay Between Cerebral Hemispheres and Cerebellum in Relation to Tonus and Movement
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Cardiology (2018)

Hospice Discharge and Outcomes in the GWTG-HF Registry 917End-of-life care is not well described for elderly patients after a heart failure (HF) hospitalization.Using American Heart Association Get With The Guidelines (GWTG)-HF registry data linked to Medicare, Warraich and coauthors assessed outcomes in 4588 patients discharged to hospice compared with 4357 patients with advanced HF and 113 045 other patients with HF in the registry.The median postdischarge survival time of patients in hospice care was 11 days; mortality within 72 hours was 34.1% in patients discharged to hospice facilities vs 12.2% discharged to home hospice.Additionally, 15.0% discharged from hospice lived for 6 months or more.In an Invited Commentary, Nakagawa and Garan comment that end-of-life care of patients with HF is difficult as treatment improves, but provision of palliative care throughout the disease trajectory is essential.
DIAGNOSTIC TEST FOR INTESTINAL PERFORATION
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal